Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2276 - Impact of age, bilirubin, and disease burden in unresectable pancreatic cancer patients receiving first-line chemotherapy: A population-based analysis


08 Oct 2016


Poster Display


Ying Wang


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


Y. Wang1, P. Camateros2, W. Cheung1

Author affiliations

  • 1 Medical Oncology, British Columbia Cancer Agency, V5Z4E6 - Vancouver/CA
  • 2 Medicine, University of British Columbia, V5Z1M9 - Vancouver/CA


Abstract 2276


FOLFIRINOX (FFN), nab-paclitaxel plus gemcitabine (NG), and gemcitabine (gem) are 3 systemic therapies that provide clinically meaningful benefit to patients with unresectable pancreatic cancer (UPC). Clinical trials have previously excluded patients with advanced age, elevated bilirubin, or locally advanced disease. Our aim was to examine whether age, bilirubin, and disease extent affected treatment outcomes.


Patients diagnosed with UPC who initiated palliative chemotherapy from August 2014 to August 2015 at any 1 of 5 cancer centers in British Columbia were identified from the provincial pharmacy. Clinical, pathological, treatment, and outcome characteristics were compared.


150 patients were included: 53% men, 78% ECOG 0/1, and 71% with metastatic disease. Patients who received FFN and NG were younger (p 


Receipt of FFN and NG portended a better prognosis than gem alone. In the absence of a randomized comparison of all 3 regimens, our population-based study revealed that the introduction of modified FFN and NG confers real world effectiveness for UPC patients regardless of age and bilirubin at presentation.

Clinical trial identification


Legal entity responsible for the study

Ying Wang




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings